[Federal Register Volume 80, Number 111 (Wednesday, June 10, 2015)]
[Notices]
[Pages 32969-32971]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-14095]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will
[[Page 32970]]
be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
Boron Amino Acid Mimetics for PET Imaging of Cancer
Description of Technology: Available for licensing and commercial
development as imaging agents for positron emission tomography of
cancer are boramino acid compounds. The inventors showed that mimetics
created by substituting the carboxylate group (-COO-) of an
amino acid with trifluoroborate (-BF3-) are
metabolically stable and allow for the use of fluorene-18 (\18\F) as
the radiolabel. Using boroamino acid for \18\F-labeling allows for
integrating the \18\F radiolabel into the core molecular backbone
rather than the side-chains thus increasing the agent's target
specificity. There is a direct relationship between amino acid uptake
and cancer cell replication, where the uptake is extensively
upregulated in most cancer cells. This uptake increases as cancer
progresses, leading to greater uptake in high-grade tumors and
metastases. Amino acids act as signaling molecules for proliferation
and may also reprogram metabolic networks in the buildup of biomass.
This invention provides for an unmet need for traceable amino acid
mimics, including those based on naturally-occurring amino acids, which
may be non-invasively detected by imaging technology, including for
clinical diagnosis and anti-cancer drug evaluation.
Potential Commercial Applications:
Cancer imaging
Anti-cancer drug development
Competitive Advantages:
Fluorene-18 labeling
Metabolic stability
Development Stage:
Early-stage
In vitro data available
In vivo data available (animal)
Inventors: Xiaoyuan Chen and Zhibo Liu (NIBIB)
Publications:
1. Liu Z, et al. Preclinical evaluation of a high-affinity 18F-
trifluoroborate octreotate derivative for somatostatin receptor
imaging. J Nucl Med. 2014 Sep;55(9):1499-505. [PMID 24970911]
2. Liu Z, et al. (18)F-trifluoroborate derivatives of [des-
arg(10)]kallidin for imaging bradykinin b1 receptor expression with
positron emission tomography. Mol Pharm. 2015 Mar 2;12(3):974-82. [PMID
25629412]
Intellectual Property: HHS Reference No. E-135-2015/0--US
Provisional Patent Application 62/155,085 filed April 30, 2015
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019 or
301-402-5579; [email protected]
Collaborative Research Opportunity: The National Institute of
Biomedical Imaging and Bioengineering is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize Boramino Acid
Mimetics for Use in Cancer Imaging. For collaboration opportunities,
please contact Cecilia Pazman at [email protected].
Resolution Enhancement for Light Sheet Microscopy Systems
Description of Technology: The invention pertains to a technique
for enhancing the resolution of images in light sheet microscopy by
adding additional enhanced depth-of-focus optical arrangements and high
numerical aperture objective lenses. The technique employs an
arrangement of three objective lenses and a processor for combining
captured images. The image composition utilizes the greater resolving
power of the third high numerical aperture objective lens by imaging
the light sheet and enhanced depth-of-focus arrangement resulting in
improved overall resolution of the light sheet system. The depth of
field arrangement could be a simple oscillation of the third objective,
a ``layer cake,'' or cubic phase mask component. Any loss in lateral
resolution that results from the depth of field arrangement may be
compensated for by deconvolution. In some embodiments, other optics,
such as an axicon or annular aperture, can provide extended depth of
field.
Potential Commercial Applications:
High speed imaging
Fast single cell and cellular dynamics imaging
Superresolution and single molecule imaging
3D single particle tracking
3D superresolution imaging in thick samples
Competitive Advantages: Resolution enhancement in light microscopy
Development Stage: In vitro data available
Inventors: Hari Shroff (NIBIB), Yicong Wu (NIBIB), Sara Abrahamsson
Intellectual Property: HHS Reference No. E-232-2014/0--US
Application No. 62/054,484 filed September 24, 2014
Related Technology: HHS Reference No. E-078-2011/0
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019 or
301-402-5579; [email protected]
Collaborative Research Opportunity: The National Institute of
Biomedical Imaging and Bioengineering is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize Resolution
Enhancement Technique for Light Sheet Microscopy Systems. For
collaboration opportunities, please contact Cecilia Pazman at 301-594-
4273 or [email protected].
Device for Selective Partitioning of Frozen Cellular Products
Description of Technology: Cryopreservation using liquid nitrogen
frozen polyvinyl bags allows for storing cellular materials for
extended periods while maintaining their activity and viability. Such
bags are commonly used in the clinic to store blood products including
blood cells, plasma, hematopoietic stem cells, umbilical cord blood for
future uses including transplantation. These materials, typically
obtained in limited quantities, may be of great therapeutic value, as
is the case of stem cells or cord blood derived cells which can be used
to potentially treat a number of diseases. Currently, even if only a
small portion of the cryopreserved sample is needed the whole bag must
be thawed, wasting much of the sample or rendering the remaining sample
susceptible to contamination since it cannot be effectively refrozen or
sterilized. The present device meets an unmet need for retrieving a
portion of a frozen sample stored in polyvinyl cryopreserved bags,
resealing the remainder of the sample and preserving the cryopreserved
state and integrity of the rest of the cellular product without
compromising viability and sterility.
Potential Commercial Applications:
Cryopreservation
Cellular Products
Hematopoietic stem cells
Umbilical cord blood
iPSCs
Transplantation
Chronic spinal cord injury
Neurological disorders
Cancer immunotherapy
Cell banking
Cell replacement therapy
Competitive Advantages:
Partitioning cryopreserved cell products
Maintenance of sterility of partitioned product
Maintenance of viability of partitioned product
Resealing of cryopreservation bag
Multiple use of patient derived cellular products
Development Stage: Prototype
Inventors: Richard Childs, Sumithira Vasu, Herb Cullis, PJ
Broussard, Kevin
[[Page 32971]]
Clark, Eric Harting (all rights assigned to the US Government)
Intellectual Property: HHS Reference No. E-173-2009/0 -
US Provisional App. 61/175,131
Int'l App. PCT/US2010/033575
Canadian App. 2,760,363
EP App. 10719496.1
IL App. 216085
US Patent 8,790,597
US Patent App. 14/305,578
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019 or
301-402-5579; [email protected]
Collaborative Research Opportunity: The National Heart, Lung, and
Blood Institute is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize Device for Partitioning Cryopreserved
Cellular Products. For collaboration opportunities, please contact
Cecilia Pazman, Ph.D. at 301-594-4273 or [email protected].
Dated: June 4, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-14095 Filed 6-9-15; 8:45 am]
BILLING CODE 4140-01-P